Table 2.

Therapeutic approaches to recalibrate apoE functions by increasing lipidation.

Class	Description	Example	References
ABCA1 agonist	Antisense oligonucleotides	miR-33 ARF6	[104] [105]
	Small peptides	CS-6253 Ac-hE18A-NH2 4F	[73], [106,107] [108] [73], [109,110,111]
Nuclear Receptor agonist	LXR agonist	TO901317 GW3965	[112,113,114] [112,113,114]
	RXR agonist	Bexarotene LG100268 SPF1 and SPF2	[115,116,117,118,119] [115,116,117] [120,121]
Structure corrector	Small molecule that corrects apoE4 structure	PH002 GIND105 and GIND-25	[122] [123,124,125]
Immunotherapy	Targets non-lipidated apoE4	HAE-1 and HAE-4	[126,127]
Biologics	AAV-directed therapy	AAV-expressing human APOE2 gene	[84], [128,129,130,131]